What's happened
Lilly and Novo Nordisk have surpassed forecasts in Q2, widening the gap in the obesity-drug space. Lilly leads in the US with about 61% share; Novo raises full-year outlook but faces questions about Wegovy's growth and its pipeline. Investors are watching whether Novo can sustain momentum as competition intensifies.
What's behind the headline?
Analysis
- Lilly has built a bigger early lead in the global incretin market, driven by Mounjaro and Zepbound.
- Novo Nordisk is pursuing momentum with Wegovy’s oral form, but needs sustained pipeline progress to match Lilly’s growth trajectory.
- Investor confidence hinges on the durability of pipeline diversification and ability to counter price pressures in the US market.
- The competition is shaping a broader shift toward more cost-effective, high-efficacy obesity therapies, potentially redefining patient access and payer dynamics in the coming years.
How we got here
The market for GLP-1 obesity and diabetes drugs is expanding globally, with Lilly and Novo Nordisk competing for dominance. Lilly has benefited from strong demand for Mounjaro and Zepbound, while Novo has pushed Wegovy (oral and injectable) to regain market share after pricing pressure and pipeline concerns persisted in 2025.
Our analysis
CNBC reports that Lilly outperformed expectations and widened its market share, while Novo Nordisk’s results showed mixed signals on Wegovy’s performance but reflected renewed guidance. Analysts express concern over Wegovy’s growth trajectory and Novo’s longer-term pipeline, as per CNBC coverage and market commentary from Jefferies, Citi, and Bernstein.
Go deeper
- Will Novo’s Wegovy strategy sustain momentum against Lilly’s Mounjaro and Zepbound?
- What does the Wegovy pill launch mean for the US obesity drug market share in 2027?
More on these topics
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
Eli Lilly and Company - Pharmaceutical company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a